סטרוקורט 4 מ"ג - Sterocort 4 mg

Rheumatology: - Active phases of systemic vasculitis: Panarteritis nodosa (in patients with concomitant positive hepatitis B serology, the duration of treatment should be restricted to two weeks), polymyalgia rheumatica (PMR), PMR with giant cell arteritis, arteritis temporalis with acute visual loss;- Active phases of systemic rheumatic disease: systemic lupus erythematosus, mixed connective tissue disease;- Severe progressive forms of active rheumatoid arthritis, e.g. rapidly destructive forms and/or with extra-articular manifestations;- Other forms of inflammatory rheumatic arthritis, provided that the severity of symptoms requires it and non-steroidal anti-inflammatory drugs (NSAIDs) cannot be used:Spondylarthritis (ankylosing spondylitis with involvement of peripheral joints, psoriatic arthritis, enteropathic arthropathy with high inflammatory activity);- Reactive forms of arthritis;- Arthritis in sarcoidosis;- Severe systemic form of juvenile idiopathic arthritis (Still’s disease) or with iridocyclitis refractory to topical treatment.Pulmonary and respiratory tract disorders: - Bronchial asthma:For the long-term treatment of severe chronic asthma (category 4) and for treatment of exacerbations in adults and children.- Chronic obstructive pulmonary disease (COPD):For short-term treatment (max. 14 days) of exacerbations;- Upper respiratory tract disorders:For short-term treatment of severe forms of allergic rhinitis in adults after failure of all other treatment alternatives, including topical glucocorticoids.Dermatology: - Oral initial treatment of extensive, severe, acute skin conditions responsive to glucocorticoids, such as: Allergic skin disease (e.g. acute urticaria, contact dermatitis, drug eruption), atopic eczema (acute exacerbations or extensive weeping eczema), pemphigus vulgaris.Nephrology: - Minimal change glomerulonephritis;- Extracapillary proliferative glomerulonephritis (rapidly progressive glomerulonephritis), generally in combination with cytostatics, tapering and ending treatment in Goodpasture’s syndrome; for all other forms, long-term continuation of treatment;- Idiopathic retroperitoneal fibrosis.